<!doctype html><html lang="en"><head><meta charset="utf-8"> <title>Life after Eroom’s law - Refoundable</title> <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover"> <meta name="description" content="An interview with Jack Scannell, who coined the term Eroom's law, on the state of drug R&amp;D, the end of an era, and the future of drug discovery."> <meta name="theme-color" content="#061E29"> <link rel="alternate" href="/feed.xml" type="application/atom+xml"> <link rel="apple-touch-icon" href="/apple-touch-icon.png"><link rel="icon" href="/favicon.png" type="image/png"><link rel="icon" href="data:image/svg+xml;utf8,%3Csvg%20width%3D'256'%20height%3D'256'%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%3E%3Cg%20fill%3D'none'%20fill-rule%3D'evenodd'%3E%3Cpath%20fill%3D'%23061E29'%20d%3D'M0%200h256v256H0z'%2F%3E%3Cpath%20d%3D'M113.2%20113H87V63.4H136c10.3%200%2020.9.2%2029.9%206a34.8%2034.8%200%200114.8%2029c0%2013.2-7.7%2025.4-20.2%2030l26.9%2065h-30L134%20133.9H73l-15.6-19.1h70.7c5.7%200%2011.9.5%2016.8-2.4%204.5-2.7%206.9-8.2%206.9-13.3%200-4.6-2.8-9.6-6.7-12-4.6-2.9-12.5-2.2-17.6-2.2h-14.4v28zm1%2022.7v44.2H86.8v-44.2H114z'%20fill%3D'%23FFF'%2F%3E%3C%2Fg%3E%3C%2Fsvg%3E" sizes="any" type="image/svg+xml"><link rel="mask-icon" href="/mask-icon.svg" color="#061E29"> <link rel="manifest" href="/manifest.json"> <style>:root{--fontstack-prefix:-apple-system,BlinkMacSystemFont,;--fontstack-sans-serif:"Helvetica Neue",sans-serif;--fontstack-serif:Georgia,serif;--fontstack-monospace:Menlo,Consolas,monospace;--fontstack-default:var(--fontstack-prefix) var(--fontstack-sans-serif);--font-size:1.6vw;--font-features:"halt","ss01","ss02";--line-height:calc(20 / 14);--heading-letter-spacing:-.04em;--breakpoint-lg:1600px;--breakpoint-md:1080px;--breakpoint-sm:640px;--breakpoint-xs:400px;--space-lg:24vw;--space-md:8vw;--space-sm:4vw;--space-xs:1.2vw;--border-lg:4px;--border-md:2px;--border-sm:1px;--link-color:#03549b;--background-color:#fff;--text-color:#000;--code-color:#3914b3;--nav-padding:.75vmax;--nav-item-space:1.4vmax}*,::after,::before{padding:0;margin:0;box-sizing:border-box}html{font-size:100%;-webkit-text-size-adjust:none;-ms-text-size-adjust:none;text-size-adjust:none;text-rendering:optimizelegibility;image-rendering:optimizequality;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;background:var(--bg-color)}body{--space-body:var(--space-lg);padding-top:0;padding-bottom:0;padding-left:var(--space-body);padding-right:var(--space-body);margin:0 auto 0;font-family:var(--fontstack-default);font-size:var(--font-size);font-feature-settings:var(--font-features);line-height:var(--line-height);hanging-punctuation:first allow-end;color:var(--text-color);background:var(--bg-color);-webkit-transition:all .2s ease;transition:all .2s ease}@media (max-width:1080px){body{--space-body:var(--space-md);font-size:calc(var(--font-size) * 1.4)}}@media (max-width:640px){body{--space-body:var(--space-sm);font-size:calc(var(--font-size) * 2.4)}}@media (max-width:400px){body{font-size:calc(var(--font-size) * 3.2)}}a{color:var(--text-color);text-decoration:none;-webkit-transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease;transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease}a:focus,a:hover{-webkit-transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;text-decoration:underline}hr,img{border:0}::-webkit-input-placeholder{color:var(--text-color);opacity:.2}::-moz-placeholder{color:var(--text-color);opacity:.2}:-ms-input-placeholder{color:var(--text-color);opacity:.2}::-ms-input-placeholder{color:var(--text-color);opacity:.2}:focus::-webkit-input-placeholder{color:var(--link-color)}:focus::-moz-placeholder{color:var(--link-color)}:focus:-ms-input-placeholder{color:var(--link-color)}:focus::-ms-input-placeholder{color:var(--link-color)}.navigation{padding-top:var(--nav-padding);padding-bottom:var(--nav-padding);margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:90%;font-weight:700}.navigation li{display:inline-block;line-height:2}.navigation li a{padding:.5em var(--nav-item-space)}.navigation li a:focus,.navigation li a:hover{color:var(--link-color);text-decoration:none}.content{margin-bottom:16vmin}.content::after,.content::before{display:table;content:""}.content::after{clear:both}.content article>:last-child{margin-bottom:0!important}.content a{font-weight:700}.content a:has(>code){-webkit-text-decoration-color:var(--code-color);text-decoration-color:var(--code-color)}.content p{margin-bottom:1.6rem;line-height:calc(var(--line-height) * 1.2)}.content h2,.content h3{margin:10vmin 0 1rem;font-size:72%;font-weight:400;opacity:.5}.content ol,.content ul{margin-bottom:1.8rem;list-style:none;counter-reset:list}@media (max-width:640px){.content ol,.content ul{margin-left:1em}}.content ol li,.content ul li{line-height:calc(var(--line-height) * 1.2)}.content ol li::before,.content ul li::before{position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none}.content ul li::before{content:"-";padding-right:.5em}.content ol li::before{counter-increment:list;content:counter(list) ".";padding-right:.25em}.content img{--space-deco:var(--space-md);display:block;width:calc(100% + var(--space-deco) * 2);margin-left:calc(var(--space-deco) * -1);margin-right:calc(var(--space-deco) * -1);margin-bottom:1.8rem}@media (max-width:1080px){.content img{--space-deco:var(--space-md)}}@media (max-width:640px){.content img{--space-deco:var(--space-sm)}}.content hr::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.content sup{font-size:75%}.footnotes{font-size:80%}.footnotes::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.footer{padding:0 0 16vmin;margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:80%;text-transform:lowercase}.footer ul li{display:inline-block;line-height:1.8}.footer ul li a{padding:.5em var(--nav-item-space)}@media print{*,::after,::before{background:0 0!important;color:#000!important;box-shadow:none!important;text-shadow:none!important}body{padding:10mm!important;margin:0!important;font-size:calc(var(--font-size) * 1.35)}a,a:visited{text-decoration:none}img{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.footer,.navigation{display:none}}:root{--rdmz-h:var(--code-color-h, 253.962264151);--rdmz-s:var(--code-color-s, 79.8994974874%);--rdmz-l:var(--code-color-l, 39.0196078431%)}body,html{max-width:100%;overflow-x:hidden}body{height:100%;width:100%;margin:0}.content{margin-bottom:0}.content h2,.content h3{opacity:1;margin:0}.content ul li::before{content:"\2022"}.content hr::before{margin:0 auto;height:0;width:0}.txt-wrap{white-space:nowrap}.content a,a,figcaption,ol li,p,span,ul li{font-weight:var(--reg-w)}.essay .head,.essay .rubric,.essay .title,.essay h2,.essay h2 a,.essay h3{font-weight:var(--sem-w)!important}.essay .cta,.essay .cta a{font-weight:var(--reg-w)!important}a:focus::-webkit-input-placeholder{color:var(--m-blue)}a:focus::-moz-placeholder{color:var(--m-blue)}a:focus:-ms-input-placeholder{color:var(--m-blue)}a:focus::-ms-input-placeholder{color:var(--m-blue)}.essay .title,.essay h2{letter-spacing:-.04em}.essay .head,.essay h3{letter-spacing:-.065em}.essay .cta,.essay .cta a,.essay ol li,.essay p{letter-spacing:-.025em}.navigation{font-weight:var(--reg-w);text-align:center;letter-spacing:-.025em;margin:var(--nil) var(--full-wid);background-color:var(--x-black);padding:0}.navigation li{padding:.5em 0}.navigation li a{color:var(--xx-white)}.navigation li a:focus,.navigation li a:hover{color:var(--xm-silver)!important}.navigation #logomark a svg{width:1.2em;height:1.2em;margin-bottom:-.15rem}.rg-aro{border-right:1px solid;border-bottom:1px solid}.bo-aro{border-right:1.5px solid;border-bottom:1.5px solid}.sh-aro{height:.4em;width:.4em;display:inline-block;color:var(--m-blue)}.tp-aro{height:.5em;width:.5em;display:inline-block;color:var(--xxx-silver)}.d-aro{-webkit-transform:rotate(45deg);transform:rotate(45deg)}.u-aro{-webkit-transform:rotate(-135deg);transform:rotate(-135deg)}.ext-aro-bs{position:relative;display:inline-block;vertical-align:middle;color:var(--m-blue);box-sizing:border-box}.ext-aro-bs:after,.ext-aro-bs:before{content:"";box-sizing:border-box}.ext-aro-fo{width:.45em;height:.45em;border-width:1px 1px 0 0;border-style:solid;margin:0 0 1px .3em}.ext-aro-fo:before{right:0;top:-1px;position:absolute;height:1px;box-shadow:inset 0 0 0 32px;-webkit-transform:rotate(-45deg);transform:rotate(-45deg);width:.7em;-webkit-transform-origin:right top;transform-origin:right top}.fn-ext-lnk{margin-left:.15em}.essay-nav{font-weight:var(--reg-w);font-size:82%;text-align:center;letter-spacing:-.025em;margin:var(--nil) var(--full-wid) -5vh;padding:0;z-index:1;border-bottom:1px solid var(--x-silver)}.essay-nav ul{margin-bottom:0}.essay-nav ul li{display:inline-block;line-height:2;padding:.5em 0}.essay-nav ul li:before{display:none}.essay-nav a.sticky-btn{font-weight:var(--reg-w);padding:.3em 1em;margin:0 1em;color:var(--l-black);text-decoration:none;-webkit-transition:none;transition:none}.essay-nav a.sticky-btn:hover{opacity:.7}.essay{counter-reset:count-fn 0 count-qst 0;margin:0 auto}.essay a{color:var(--m-blue)}.essay ol li,.essay p{line-height:1.35;color:var(--xm-black)}.essay ol li{margin-bottom:.3em}.essay hr{padding:0 0 8vw}.essay .essay-header{padding:8vw 0}.essay .callout{text-align:center}.essay .callout .title{color:var(--xm-silver);text-decoration:none;margin:0}.essay .callout .head{line-height:1;color:var(--x-black)!important;margin:0 0 .3em}.essay .callout .deck{margin:0 auto}.essay .callout .byline{display:none}.essay .callout .cta{margin:0;padding-top:.7rem}.essay .callout .cta a{color:var(--m-blue)!important;font-weight:var(--reg-w)!important;padding-right:.2rem;padding-bottom:.2em;margin-left:1%}.essay .callout .po-aro{margin-bottom:.2em;margin-left:.2em}.essay .callout .rubric{margin:0 auto -1.5em;color:var(--m-accent);position:relative;top:-1.8em;text-transform:uppercase}.essay .section-headings{position:relative;padding-top:8vw!important}.essay .section-headings h2 a{color:var(--xm-silver);text-decoration:none;padding:8vw 0 0}.essay .section-headings h3{line-height:1;color:var(--x-black)!important;max-width:65%}.essay figure figcaption{font-weight:var(--reg-w);color:var(--m-gray);text-align:center;padding-top:.5rem;margin:auto}.essay figure .credits{color:var(--x-silver);font-size:95%}.essay figure .credits-blk{display:block}.essay .qst{margin-top:-1em;padding-top:2.2em;font-weight:var(--med-w)}.essay .qst::before{color:var(--m-gray);counter-increment:count-qst;content:counter(count-qst) ".";position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none;padding-right:.25em}.essay .qst-lnk{padding:.2em .3em!important;margin-right:-1.5em}.essay .qst-lnk svg{fill:var(--m-gray);opacity:.4;vertical-align:middle}.essay .fn-btn{background-color:var(--l-silver);position:relative;margin-left:.3em;color:var(--m-gray);font-weight:var(--sem-w);font-size:90%;text-decoration:none}.essay .fn-btn:hover{background-color:var(--xl-silver)}.essay .fn-btn:focus{outline:0}.essay .fn-btn-top{padding:.25em 1em .35em!important;top:.35em;margin-left:.2em}.essay .fn-btn-bot{padding:.35em .8em .3em!important;margin-left:.5em;top:.1em}.essay sup{padding-top:25vh;margin-top:-25vh}.essay .footnotes{font-size:inherit;padding-bottom:2.2vw;border-top:1px solid var(--m-silver);padding-top:2em}.essay .footnotes:before{display:none}.essay .footnotes p{line-height:1.5}.essay .footnotes ol li{display:-webkit-box;display:flex}.essay .footnotes ol li:before{color:var(--m-gray);position:relative;display:inline-block;counter-increment:count-fn;content:counter(count-fn) "."}.footer{text-align:center}.footer a,.footer p{margin:0 .2em;padding:0 .1em!important}.footer a,.footer p,.footer ul{display:inline-block;text-transform:capitalize}.footer ul li:before{content:" "!important;display:none}.footer .return-top{text-align:center;margin-bottom:6vh}.footer .return-top a{font-size:130%;text-decoration:none;padding:.15em .85em .25em!important;border-radius:7px;margin-left:.2em}.footer .return-top a:hover{text-decoration:none}.footer-light{padding:0;margin:4vh auto 3vh}.footer-light a,.footer-light p{color:var(--xxx-silver)}.footer-light .return-top a{background-color:var(--l-silver)}.footer-light .return-top a:hover{background-color:var(--xl-silver)}:root{--reg-w:400;--med-w:500;--sem-w:600;--lg-rubric:70%;--lg-title:210%;--lg-head:395%;--lg-deck:140%;--lg-cta:130%;--lg-bghead:440%;--lg-subhead:160%;--lg-bgcta:150%;--md-rubric:80%;--md-title:240%;--md-head:450%;--md-deck:160%;--md-cta:150%;--md-bghead:450%;--md-subhead:180%;--md-bgcta:170%;--sm-rubric:90%;--sm-title:230%;--sm-head:370%;--sm-deck:180%;--sm-cta:170%;--sm-bghead:430%;--sm-subhead:200%;--sm-bgcta:180%;--xs-rubric:65%;--xs-title:170%;--xs-head:280%;--xs-deck:130%;--xs-cta:130%;--xs-bghead:330%;--xs-subhead:155%;--xs-bgcta:140%;--lg-nav:90%;--md-nav:120%;--sm-nav:140%;--xs-nav:110%;--lg-txt:130%;--md-txt:150%;--sm-txt:170%;--xs-txt:130%;--lg-fn:100%;--mo-fn:80%;--lg-fig:90%;--md-fig:115%;--sm-fig:130%;--xs-fig:95%;--lg-not:110%;--md-not:140%;--sm-not:160%;--xs-not:120%;--lg-foo:80%;--md-foo:105%;--sm-foo:120%;--xs-foo:90%;--xx-black:#0d0d0d;--x-black:#111;--xm-black:#222;--m-black:#272727;--l-black:#333;--xl-black:#444;--m-gray:#555;--m-blue:#03549b;--xx-white:#fff;--xxx-silver:#898989;--xx-silver:#aaa;--x-silver:#bbb;--bf-silver:#bfbfbf;--xm-silver:#cfcfcf;--m-silver:#ddd;--l-silver:#eee;--xl-silver:#e7e7e7;--m-accent:#805e03;--vl-accent:#f6f6f6;--nil:0;--full-wid:-50%;--space-lg:21vw}@font-face{font-family:Barlow;font-style:normal;font-weight:400;src:local("Barlow Regular"),local("Barlow-Regular"),url(https://fonts.gstatic.com/s/barlow/v4/7cHpv4kjgoGqM7E_DMs5ynghnQ.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:Barlow;font-style:italic;font-weight:400;src:local("Barlow Italic"),local("Barlow-Italic"),url(https://fonts.gstatic.com/s/barlow/v4/7cHrv4kjgoGqM7E_Cfs7wH8Dnzcj.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:500;src:local("Barlow Medium"),local("Barlow-Medium"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E3_-gs51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:600;src:local("Barlow SemiBold"),local("Barlow-SemiBold"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E30-8s51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:system-ui;font-style:normal;font-weight:400;src:local(".SFNSText-Regular"),local(".HelveticaNeueDeskInterface-Regular"),local(".LucidaGrandeUI"),local("Segoe UI"),local("Ubuntu"),local("Roboto-Regular"),local("DroidSans"),local("Tahoma")}@font-face{font-family:system-ui;font-style:normal;font-weight:600;src:local(".SFNSText-Medium"),local(".HelveticaNeueDeskInterface-MediumP4"),local(".LucidaGrandeUI"),local("Segoe UI Semibold"),local("Ubuntu Medium"),local("Roboto-Medium"),local("DroidSans-Bold"),local("Tahoma Bold")}:root{--font-size:1.3vw;--fontstack-prefix:'Barlow','Barlow-Local',system-ui;--fontstack-sans-serif:'Barlow','Barlow-Local',system-ui,sans-serif}html{font-family:Barlow,Barlow-Local,system-ui,sans-serif}@media screen and (max-width:799px){.navigation li{padding:.6em .3em;margin:0 .5em 0 0}.essay-nav{display:none}.essay{max-width:100%}.essay p{max-width:94%;line-height:1.4}.essay ol,.essay p{margin-left:3%;margin-bottom:1.2em}.essay ol{max-width:97%;margin-left:0!important}.essay ol li{margin-left:1.5em;line-height:1.4}.essay .callout{margin:0 auto 6vw!important;padding:15% 0 20%}.essay .callout .cta a{letter-spacing:-.025em}.essay .section-headings{margin-bottom:8vw;left:3%;max-width:100%}.essay figure{margin:11% auto 10%}.essay figure img{width:110%;margin-bottom:0}.essay figure figcaption{max-width:95%}.essay .qst{margin-top:1.2em}.essay .qst::before{margin-top:-1.8em;margin-left:0;font-size:80%;font-weight:var(--sem-w);background-color:#dfdfdf;content:counter(count-qst);width:2em;-webkit-box-pack:center;justify-content:center;text-align:center;padding-right:0}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin-top:10vw}.essay .footnotes ol li::before,.essay .footnotes p{font-size:var(--mo-fn)}.essay .footnotes p{margin-left:0;max-width:90%}.essay .footnotes ol li{margin-left:0;padding-top:11vh;margin-top:-11vh}.essay .footnotes ol li:before{margin-top:.05em;margin-left:-2.3em}.essay #deck-mis{max-width:100%}.footer ul{margin-left:0}}@media screen and (max-width:400px){.navigation{font-size:var(--xs-nav)}.essay .rubric{font-size:var(--xs-rubric)}.essay .title,.essay h2{font-size:var(--xs-title)!important}.essay .head,.essay h3{font-size:var(--xs-head)}.essay .deck{font-size:var(--xs-deck)}.essay .cta{font-size:var(--xs-cta)}.essay ol li,.essay p{font-size:var(--xs-txt)}.essay figure{font-size:var(--xs-fig)}.footer{font-size:var(--xs-foo)}}@media screen and (min-width:401px) and (max-width:639px){.navigation{font-size:var(--sm-nav)}.essay .rubric{font-size:var(--sm-rubric)}.essay .title,.essay h2{font-size:var(--sm-title)!important}.essay .head,.essay h3{font-size:var(--sm-head)!important}.essay .deck{font-size:var(--sm-deck)!important}.essay .cta{font-size:var(--sm-cta)}.essay ol li,.essay p{font-size:var(--sm-txt)}.essay figure{font-size:var(--sm-fig)}.footer{font-size:var(--sm-foo)}}@media screen and (min-width:640px) and (max-width:799px){.navigation{font-size:var(--md-nav)}.essay .rubric{font-size:var(--md-rubric)}.essay .title,.essay h2{font-size:var(--md-title)!important}.essay .head,.essay h3{font-size:var(--md-head)}.essay .deck{font-size:var(--md-deck)!important}.essay .cta{font-size:var(--md-cta)}.essay ol li,.essay p{font-size:var(--md-txt);margin-left:0}.essay figure{font-size:var(--md-fig)}.footer{font-size:var(--md-foo)}.navigation li{margin:0 2em 0}.essay{max-width:95%}.essay ol li{margin-left:0}.essay p{max-width:100%}.essay .section-headings{margin-bottom:6vw;left:0}.essay figure img{width:100%;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:80%}.essay .qst{margin-top:-1em}.essay .qst::before{margin-top:0;margin-left:-4em;font-size:100%;font-weight:var(--reg-w);background-color:transparent;width:4em;content:counter(count-qst) ".";-webkit-box-pack:end;justify-content:flex-end;text-align:right;padding-right:.25em}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin:10vw auto 0 -1.75em;max-width:100%}.essay .footnotes ol,.essay .footnotes p{max-width:100%;width:100%}.essay .footnotes ol li:before{margin-left:0;width:1.5em}.essay #deck-mis{max-width:85%}}@media screen and (min-width:800px){.navigation{font-size:var(--lg-nav)}.essay .rubric{font-size:var(--lg-rubric)}.essay .title,.essay h2{font-size:var(--lg-title)!important}.essay .head,.essay h3{font-size:var(--lg-head)}.essay .deck{font-size:var(--lg-deck)!important}.essay .cta{font-size:var(--lg-cta)}.essay ol li,.essay p{font-size:var(--lg-txt)}.essay figure{font-size:var(--lg-fig)}.essay .footnotes ol li,.essay .footnotes p{font-size:var(--lg-fn)}.footer{font-size:var(--lg-foo)}.navigation li{padding:.5em 0}.navigation li a{padding:.3em 1em;margin:0 2.5em}.navigation #logomark{margin-left:3%}.essay-nav{display:none}.essay{max-width:95%}.essay ol li,.essay p{max-width:86%;margin-left:5%}.essay .callout{margin:0 auto!important;padding:4% 0 10%}.essay .section-headings{margin-bottom:5vw;left:-1.5em}.essay figure{margin:10% auto 9%}.essay figure img{width:100%;max-width:1200px;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:65%}.essay .fn-btn{border-radius:7px}.essay .footnotes{max-width:100%;margin:8vw auto 0 .9em}.essay .footnotes ol li{padding-top:9vh;margin-top:-9vh;max-width:100%;margin-left:0}.essay .footnotes ol li p{margin-left:0}.essay .footnotes ol li:before{margin-left:-2.75em}.essay #deck-mis{max-width:80%}}@media screen and (min-width:1080px){.essay-nav{display:block}.essay-nav-scroll{position:fixed!important;width:100%!important;top:0;left:50%;-webkit-transition:background-color .5s cubic-bezier(.28,.11,.32,1);transition:background-color .5s cubic-bezier(.28,.11,.32,1);border-bottom-color:var(--xl-black)!important;background-color:var(--l-black)!important}.essay-btn-scroll{color:var(--xl-silver)!important}.essay{max-width:93%}.essay ol li,.essay p{max-width:91%}.essay figure figcaption{max-width:70%}.essay #deck-mis{max-width:80%}}</style> <link href="https://fonts.googleapis.com/css?family=Barlow:400,400i,500,600&amp;display=swap" rel="stylesheet"> <link rel="canonical" href="https://refoundable.com/scannell"> <meta property="og:type" content="article"> <meta property="og:site_name" content="Refoundable"> <meta property="og:title" content="Life after Eroom’s law"> <meta property="og:url" content="https://refoundable.com/scannell"> <meta property="og:description" content="An interview with Jack Scannell, who coined the term Eroom's law, on the state of drug R&amp;D, the end of an era, and the future of drug discovery."> <meta property="og:image" content="https://refoundable.com/assets/img/og-iconic.png"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@refoundable"> </head><body><nav id="top" class="navigation"> <ul> <li id="logomark"> <a href="/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 200"><path d="M85.7 76H45.2V0h75.6c16 0 32.2.3 46.1 9.1a53.5 53.5 0 0122.8 44.7 48.4 48.4 0 01-31.2 46.1L200 200h-46l-36.3-91.7H24L0 78.8h108.9c8.7 0 18.1.8 25.8-3.7a24.2 24.2 0 0010.5-20.5c0-7-4.2-14.7-10.3-18.3-7-4.5-19.2-3.4-27-3.4H85.6v43zm1.4 35v68.1h-42v-68h42z" fill="#FFF" fill-rule="evenodd"></path></svg></a> </li> <li> <a href="/mission">Mission</a> </li> <li> <a href="/soon">Research</a> </li> <li> <a href="/about">About</a> </li> </ul> </nav> <main class="content" role="main"> <script>window.onscroll=function(){window.addEventListener("scroll",stickyNav)}</script> <nav id="sticky-nav" class="essay-nav"> <ul> <li><a class="sticky-btn" href="#s1">Introduction</a></li> <li><a class="sticky-btn" href="#s2">Breakout</a></li> <li><a class="sticky-btn" href="#s3">Decline</a></li> <li><a class="sticky-btn" href="#s4">Alchemy</a></li> </ul> </nav> <article class="essay"> <div class="essay-header"> <div class="callout"> <div class="meta"> <div class="rubric">Interview&nbsp;&nbsp;•&nbsp;&nbsp;March 13, 2020</div> <div class="title">Secrets</div> </div> <h1 class="head">Life after<br>Eroom’s law.</h1> <p class="deck" id="deck-mis">An interview with Jack Scannell, who coined the term Eroom's law, on the state of drug R&amp;D, the end of an&nbsp;era,&nbsp;and the future of drug discovery.</p> <div class="byline"> <span>By John Strider</span><span>&nbsp;|&nbsp;</span> <span>Refoundable</span> </div> <div class="cta"><a href="#s1">Introduction</a><div class="rg-aro sh-aro po-aro d-aro"></div></div> </div> </div>  <div class="section-headings"> <h2><a id="s1">Introduction</a></h2> <h3>Looking past<br>the end.</h3> </div> <p>One of the founding propositions of Refoundable is that far too many people make the rational decision to look for secrets in the easy areas that have seen the most progress over the last half-century.</p> <p>A counterintuitive approach at this point may well be to start with the technology areas worst hit by neglect, stagnation and rising costs, and figure out how to restart their <span class="txt-wrap">progress.<sup><a href="#fn1" id="r1" class="fn-btn fn-btn-top">1</a></sup></span></p> <p>Take healthcare for example. While computers got faster and cheaper every year for the last five decades, healthcare costs rose faster than inflation, and average life expectancy grew by a measly eight years since <span class="txt-wrap">1970.<sup><a href="#fn2" id="r2" class="fn-btn fn-btn-top">2</a></sup></span></p> <p>Yet, unlike other stagnating technology areas like defense or nuclear energy, we can get most people to agree that healthcare is both deeply broken and crucial to fix, so on the whole, less people might try to stop us if we start there.</p> <p>Still, a full frontal attack on the healthcare question is ill-advised, as the sheer scale of the field amplifies its inertia. However, we can take a lesson from the startup world and focus on breaking through in one key area.</p> <p>Our ideal target would be a field where the more progress we make, the less effort we’d have to put in to discover new secrets. Certainly, there was a time when people thought about pharmaceuticals in those terms.</p> <p>The promise was that you could unlock the secrets of biochemistry and use them to create all sorts of life-enhancing concoctions, from a five course meal in a pill to the elixir of eternal youth.</p> <p>Instead, the pharma industry looks today, if anything, like it’s moving in the opposite direction. Every day seems to bring even less clarity on how biological systems work, and the cures seem to get only harder to find. One may reasonably ask: what went wrong?</p> <p>At first glance, it’s hard to know exactly what’s going on, as the industry puts out an overwhelming torrent of data to tell any bullish or bearish story you like. Fortunately for us, however, the field does have one robust measure of progress that can cut the hype cycle short.</p> <p>It’s called Eroom’s law, and the name is already saying a lot. It’s literally an ironic backward spelling of Moore’s law, the equivalent benchmark of progress in the computer industry, so it seems like the most fitting place to start.</p> <p style="font-weight:500">Hitting bottom</p> <p>Eroom’s law is the observation that the cost of developing a new drug roughly doubled every nine years from 1950 through the 2010. All in all, it shows an 80 fold decline in the productivity of drug R&amp;D.</p> <p>In a way, it’s hard to say which is worse, the staggering decline or the fact that it went on for six decades. Either way, as the sum total of our effort to look for life-saving secrets, Eroom’s law leaves no doubt that our ability to explore the frontier has atrophied catastrophically.</p> <figure> <img class="ful-img" alt="Eroom's law shows the staggering decline in drug R&amp;D productivity" id="img-eroom-1" src="/assets/img/buf.png" data-echo="/assets/img/eroom-1.png"> <figcaption id="cap-eroom-1">9 out of 10 drugs never make it to market, while a successful drug that cost $100M to develop in the 1960s would cost over $1 billion four decades later.<span class="credits credits-blk">Jack Scannell</span></figcaption> </figure> <p>Although some aspects of this trendline have been known since the 1980s, Eroom’s law was formally articulated only in 2012, in a seminal paper published in <em>Nature</em> by four co-authors led by Jack Scannell.<sup><a href="#fn3" id="r3" class="fn-btn fn-btn-top">3</a></sup></p> <p>In a field plagued by narrow specialization, Jack Scannell is something of a renaissance man, having seen the industry from a distance and up close while working in drug research, private consulting, pharma and biotech investing, and policy advising.</p> <p>When Scannell used to ask the top executives at major pharma firms why their drug R&amp;D productivity was so low, they would repeatedly say it was due to the exhaustion of easy targets, all while deploying billions of dollars in R&amp;D each year.</p> <p>Yet, as Scannell sees it, the problem isn’t that we’re running out of easy pickings, but that our search methods are too often inadequate to find good drug candidates. Put another way, we’re very efficiently looking in the wrong places at great expense, and predictably turning up nothing.<sup><a href="#fn4" id="r4" class="fn-btn fn-btn-top">4</a></sup></p> <p>Instead of improving its methods however, the industry has found it easier so far to pursue commercial opportunities that its methods are well suited to find. That has pushed pharma companies over the last decade into narrow markets with small patient groups, like oncology and rare diseases.</p> <p>The good news is that this shift has led to a real uptick in drug R&amp;D productivity since 2010, enough to break the trendline of Eroom’s law, but some questions remain. Will this uptick continue in the decades ahead? And, more to the point, can the industry find a way back to general progress?</p> <p>We sit down with Jack Scannell to assess the record of Eroom’s law, and discuss the state of drug R&amp;D and the future of drug discovery.</p> <div class="footnotes"> <ol> <li id="fn1"> <p>A fair question to ask is: What constitutes a technology field? Taking as a start a simple definition of technology as doing more with less, we believe that any field where some R&amp;D effort is undertaken to improve productivity counts as a technology sector. One surprising result of this definition is that Education, which accounts for over 5 percent of U.S. GDP spending at this point, would hardly qualify as a technology field, since so little of that spending goes to R&amp;D efforts to raise its productivity.<a href="#r1" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn2"> <p>According to the CDC, average life expectancy in the U.S. grew from 70.8 years in 1970 to a peak of 78.9 years in 2014, at the rate of 1.9 years per decade. By contrast, average life expectancy in the preceding four decades, from 1930 to 1970, grew at the rate of 2.7 years per decade, or 42 percent higher.<a href="#r2" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn3"> <p><em>Diagnosing the decline in pharmaceutical R&amp;D efficiency</em>, Jack Scannell, Alex Blanckley, Helen Boldon, and Brian Warrington, Nature, 2012 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/nrd3681">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r3" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn4"> <p>Is drug discovery similar to mining an exhaustible resource, as the pharma industry often argues? Jack Scannell suggests that the industry's position would be worse if that turns out to be the case, since actual extractive industries vastly outperform Pharma's record of drug discovery. The real cost of extracting a unit of oil, coal, or most commodity metals, has gotten cheaper over time, while the cost of developing a new drug has ballooned exponentially. There's also something to be said for the intuition that biology is not like a finite coal mine, and that we set our sights too low when we accept this line of argument as anything other than a rationalization of the decline that has taken place.<a href="#r4" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2><a id="s2">Breakout</a></h2> <h3>A&nbsp;diagnosis<br>gone viral.</h3> </div> <p class="qst" id="q1">Your 2012 paper in Nature showed the severe extent of the decline in drug R&amp;D productivity. What moved you to write it? And how did you settle on Eroom’s law as a name for this disturbing trend?<a class="qst-lnk" href="#q1"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>At the time, there was a lot of optimistic rhetoric around how basic science and lots of technologies important for drug discovery were getting much better.</p> <p>I was an investment analyst with a geeky interest in history of drug R&amp;D, and I had data that showed the number of new drugs approved was pretty flat, while there had been an exponential increase in R&amp;D costs over 50 years.</p> <p>It struck me as an ugly contrast that the inputs could get billions of times cheaper, while the number of drugs approved per $1 billion spent on R&amp;D had declined by roughly two orders of magnitude.</p> <p>Although many people had bemoaned the R&amp;D productivity problem before, no one had contrasted the input efficiency gains with the output efficiency decline. I thought this was an important public policy problem, and it seemed to have less focus than it should have.</p> <p>Then, during a conversation I had one day with William Baines, who has a background in venture capital and biotech, we said the drug industry looks like Moore’s law backwards, and that’s how the term Eroom’s law was born.</p> <p class="qst" id="q2">Given that, by the 1980s, the drug industry knew that R&amp;D productivity was declining, why do you think it took over three decades for a paper to formally diagnose this decline?<a class="qst-lnk" href="#q2"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>There was, too often, a very high correlation between being interested in the problem, and having a particular solution to sell.</p> <p>If, for example, you were an academic geneticist, the fact that it was a productivity problem was an opportunity to promote more investment in genomics. If you were an investment bank, you saw an opportunity to promote M&amp;A, and argue that the problem is that you have sclerotic drug companies, and they need to buy a few biotech firms, and we’re here to help. If you were a consulting firm, you would say there’s an organizational issue here, a structural problem with your company, and you need to bring us in to do a re-engineering project.</p> <p>Investment analysts are among the few people where a bad prognosis can be interesting, because if you think an industry is in real trouble, you don’t have to own it. That meant that I could take an independent look at this.</p> <p>I didn’t have to pick a solution <em>a priori</em>, nor did I have any particular solution to sell. I markedly avoided giving any helpful remedies in the paper, except to suggest that the industry did more to analyze why things went wrong.</p> <p>A lot more people would’ve been better qualified to write this paper, but strangely, their jobs made it much harder for them to write it.</p> <p class="qst" id="q3">Judging by the widespread usage of Eroom’s law, your paper was a breakout success. What was the general reaction? And how did you see the discussion change in response?<a class="qst-lnk" href="#q3"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>The immediate thing people were enthusiatic about was putting a name to things they knew were going on already.</p> <p>Apart from Eroom’s law itself, which was widely adopted, people liked something else I talked about in the paper, which I referred to as the “Better than the Beatles” problem for the following reason:</p> <p>Imagine how hard it would be to sell new pop songs if every new song had to be better than the Beatles, and you could download all the old Beatles records for free, and no one ever got bored of listening to the same songs over and over again.</p> <p>In the pharma industry, you do have those three factors, in that some old drugs are very good, and when their patents expire, they become almost free, and doctors don’t get bored of prescribing them.</p> <p>As a result, in many therapy areas, you have this ever-expanding back catalog of virtually free and very good medicine, against which new medicine would have to compete, and that tends to reduce the value of undiscovered drugs.</p> <p>Another reaction that became clear to me from reading the literature was that people appropriated the Eroom’s law paper to do what they wanted to do anyway.</p> <p>It’s like that line from the English TV comedy <em>Yes Minister</em>, “We must do something. This is something. Therefore, we must do this.” That would get modified, so that people would write papers that say: Eroom’s law tells us we must do something. Here is something. Therefore we must do this.</p> <p>Yet, apart from that, and aside from a few people in the drug industry telling me that the paper became required reading, it’s not clear to me that anything different was done after it was read.</p> <hr> <div class="section-headings"> <h2><a id="s3">Decline</a></h2> <h3>A&nbsp;chronic<br>drug&nbsp;problem.</h3> </div> <p class="qst" id="q4">R&amp;D spending kept growing for decades, even as Pharma companies lost money on their investments. Was competition a big driver behind this? At what point does R&amp;D spending turn into a race to outspend everyone else?<a class="qst-lnk" href="#q4"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Returns on R&amp;D are very stochastic. The industry makes an enormous amount of its profits from a very small number of drugs, so if you think you might have one of those drugs, then you expect your returns on R&amp;D to be relatively high.</p> <p>Even for the big companies, the economics are very sensitive to one or two products, and so long as a few people in the industry are winning, it’s very hard for other people to walk away from the game.</p> <p>As a consequence, the industry could generate poor returns for long periods of time, and the drug companies would still be unwilling to take the painful measures they would otherwise take if they were narrowly maximizing shareholder value.</p> <p>In addition, there’s an element of the agency problem at work here. A former colleague of mine, Richard Evans, put it best: few people who fight their way to the top of a drug company do so because they want to fire all the scientists and pay a bigger dividend. Typically, what they really want is to discover more drugs.</p> <p>That means that as long as some companies in the industry seem to be doing well, you can plausibly express confidence in your pipeline and scientists, and you can spend shareholders money with a clear conscience, despite the fact that, on average, you’re going to lose it.</p> <p class="qst" id="q5">How do you think the 80 fold decline in drug R&amp;D productivity over six decades has changed the Pharma industry?<a class="qst-lnk" href="#q5"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Starting in the mid-1980s, you had the rise of industrialized target-based drug discovery, which was a response to the sense that the old way of doing things i.e., the more iterative, lower throughput approach, was no longer working.</p> <p>Yet, until the 2000s, the decline in R&amp;D productivity was masked by growth in pharma markets and in drug pricing. People knew R&amp;D was getting harder, but so long as prices kept going up and markets kept growing, it didn’t seem like such a terrible problem.</p> <p>Put another way, the number of drugs approved per billion dollars of R&amp;D was dropping, but the average dollar value of each drug approved was growing.</p> <p>Anemic R&amp;D productivity only started to look more serious following the financial crisis of 2007, and this was reflected in the restructuring of the industry. Many pharma mergers at the time became a way to take out R&amp;D capacity, which was seen as inefficient and very cost-insensitive.</p> <p>You see the most extreme example of this approach with the rise of Valeant, which basically concluded that Pharma companies would be worth a lot more if they got rid of their research labs and focused solely on commercial distribution.</p> <p>For a time, this was seen by the market on Wall Street as a laudable model to be copied, until Valeant got caught up in scandal and the business model went up in flames. The pharma industry discovered that simultaneously shutting down research labs and hiking up drug prices carried insurmoutable political risk. </p> <p class="qst" id="q6">The standard list of fixes to raise R&amp;D productivity tend to focus, by and large, on process efficiency and cost-cutting. Why haven’t these solutions been enough to stop and reverse Eroom’s law?<a class="qst-lnk" href="#q6"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Simply put, they’re addressing the wrong class of problems. Suppose we were looking at the oil industry, and we found that it cost a hundred times more to produce a barrel of oil today than it did in 1950, despite the fact that your technology for pumping oil out of the ground got billions of times cheaper.</p> <p>Under those circumstances, no one would say the primary problem that the oil industry has is that the reporting lines are wrong, and we need to fix the organizational structure and get the drill procurement processes sorted out. It would be obvious that there’s a geological explanation for the problem.</p> <p>When drug companies talk to their shareholders, I suspect they talk about processes and cost cutting because that’s the sort of thing shareholders can understand. You talk less about the science and technology choices because that’s very hard to evaluate from the inside, let alone the outside.</p> <p>It’s very difficult to engage in those technical conversations, even for scientists. If you’re a cancer biologist in a drug company, it’s hard for you to assess respiratory medicine or depression. Expertise tends to be narrow.</p> <p>Even when company executives shrug their shoulders and say it’s a low-hanging fruit problem, that’s still not a very straightforward or easy conversation to have with shareholders.</p> <p>If it really is a low-hanging fruit problem, well the fruit ain’t gonna get any lower, so if you primarily blame the exhaustion of some sort of technological opportunity, you’re almost saying to your shareholders that you should shut down R&amp;D altogether.</p> <p class="qst" id="q7">In your 2012 paper, you predicted that Eroom's law wouldn'tFDA has doubled continue to hold, and indeed we've seen an uptick in R&amp;D productivity in the last decade. Why did Eroom's law come to end?<a class="qst-lnk" href="#q7"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Recently, the number of drugs approved each year by the FDA has doubled. Where we were getting 20-25 drugs a year approved before 2010, we’re running 40-50 drugs a year in the last decade.</p> <p>A very large proportion of those drugs have been for oncology and for rare diseases. These two categories have become attractive for a number of reasons:</p> <ol> <li>They are very price-insensitive markets, where the drug industry has discovered over time quite how much it can charge.</li> <li>The regulatory environment in those areas has been relatively benign.</li> <li>The target-based drug discovery that drug companies industrialized works better for genetically simple diseases, like orphan diseases and molecularly-defined cancer subtypes, where much of the pathology can be blamed on a single gene that you can isolate and characterize in the discovery process.</li> </ol> <p>Success in these therapy areas has given the industry a way to signal that they’ve turned a corner on R&amp;D productivity. The industry talks about “unmet medical needs” which is the flipside of the resource depletion problem.</p> <p>To a certain extent, this is the one way the industry has been able to talk about the problem euphemistically. These tend to be therapy areas with small patient groups, like oncology and rare diseases, where good medicinal solutions are lacking.</p> <p>It’s possible one could paint a quantitative picture of those areas where there is both unmet medical need and a tractable technological opportunity.</p> <p>I haven’t seen that sketched out, but if one tried to sketch that out in detail, one might find it smaller than shareholders would hope. So I doubt that it will have the public health impact that the great drug discovered from the 1940s through the 1970s.</p> <hr> <div class="section-headings"> <h2><a id="s4">Alchemy</a></h2> <h3>Discovery.<br>Put&nbsp;to&nbsp;the&nbsp;test.</h3> </div> <p class="qst" id="q8">The statistical approach to drug discovery implies that we still don't understand human biochemistry. We don't know what will work, so we test 10<sup>7</sup> compounds and cross our fingers. Is this the best we can do? Could we bring drug discovery closer to an engineering science?<a class="qst-lnk" href="#q8"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>The rate limiting step in drug R&amp;D has become largely to do with what people in the drug industry call “target validation” and what I would call “screening and disease model validity.”</p> <p>So is the piece of biological machinery that you think is associated with the disease, and which you can only easily experiment on outside of humans, whether in a test tube, in a rat, or with a bit of tissue in a dish, is that really going to predict what will happen when you put the drug into a real person with real disease?</p> <p>Everyone in the drug industry and in biomedical research in general knows that good models are better than bad models. But, until you run the decision-theoretic maths which very few people have done, you don’t realize that a marginally better model is maybe 10 or 100 times more productive.</p> <p>British cycling has been very successful in recent years under Dave Brailsford, and his philosophy was that if you make enough very small incremental improvements, they add up to quite substantial improvements in aggregate.</p> <p>If I’m right about the very strong quantitative relationship between small changes in model validity and R&amp;D productivity, then I actually think there’s a lot of small things that could be done by drug companies that would cumulatively have quite a big effect.</p> <p>And also, it would help if the drug industry realized that some therapeutic areas are currently unmodelable, and didn’t work on them until model quality improves.</p> <p>Finally, I strongly suspect that the world could invest more in experimental medicine, where you try and actually shift the latest stages of the drug discovery process out of animals and into humans. Over the last couple of decades, it hasn’t been very fashionable, because you know it hasn’t fit well with genomic reductionism. But I think it may well be more predictive.</p> <p class="qst" id="q9">Why isn't there enough investment in target validation?<a class="qst-lnk" href="#q9"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>The problem is there’s very robust intellectual property around chemical matter, but there isn’t such robust intellectual property around target validation.</p> <p>So if I spend a billion dollars working out a biological mechanism, and I convince myself that it works, and then I patent a drug against it, the minute that drug shows success in early stage trials, ten other companies can produce good chemistry against that target that won’t infringe my patents.</p> <p>So the economic incentives are now dissociated from the bit that’s difficult. In the 1980s, chemistry was difficult and patents were great for protecting chemistry, now it’s it’s the biological mechanism stuff that’s difficult and it’s hard for companies to appropriate that value.</p> <p>If the public authorities was amenable to this, you can either have more public sector investment in screening and disease models, or you could change intellectual property rights in such a way that you shifted incentive so the people were investing in the things that were at the rate limiting step, which at the moment are largely target validation and screening and disease models, and they’re incentivized a bit less to invest in what is no longer the rate limiting step, which is the chemistry or the therapeutic modality.</p> <p class="qst" id="q10">Over half of all new drug uses are discovered by field doctors from the existing pool of approved drugs. Biology reuses stuff, as you put it. How can we rehabilitate trial-and-error testing for drug discovery?<a class="qst-lnk" href="#q10"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Today, academic fashion, economic incentives, and intellectual property laws all work against field discovery.</p> <p>Present-day medicine is heavily influenced by an approach called evidence-based medicine, which holds that phase three randomized control trials, and meta-analyses of those trials are true and believable in a way that nothing else is.</p> <p>This is despite the fact that phase three trials typically recruit patients who are unlike the patients who get the drugs in the real world, and the meta-analyses are based on the phase three trials the drug companies chose to run.</p> <p>In other words, randomized control trials lack ecological validity, even if they manage to avoid statistical bias, whereas observational studies do risk statistical bias, but they’re conducted in patient populations who are like the patients using the drug in the real world. </p> <p>Nonetheless, this evidence-based medicine movement is very strong, and it doesn’t like things like case reports or observational studies, and that tends to keep field discovery excluded.</p> <p>In addition, once a drug goes on the market, the patent expiry clock starts ticking, and that makes it very difficult to invest substantially in the kind of evidence that would back up the field discoveries.</p> <p>So you have the problem that here seems to be an effective and valid way of finding out what drugs do, but it’s economically unexploitable.</p> <p>In principle, a world in which high-fidelity data on patient responses to pharmacology is systematically captured and analyzed could do great things for this kind of serendipitous, in-man, user-led innovation.</p> <hr class="hr-show"> </article> <div style="display:none"><span class="essay-nav-scroll"></span><span class="essay-btn-scroll"></span></div> </main> <footer id="footer-main" class="footer footer-light"> <div class="return-top"><a href="#top"><div class="bo-aro tp-aro u-aro"></div></a></div> <p>© 2019–<span id="current-year">2020</span> Refoundable LP</p> <ul> <li> <a href="/privacy">Privacy</a> </li> <li> <a href="/terms">Terms</a> </li> <li> <a href="/about#contact">Contact</a> </li> </ul> </footer> <script></script> <script>function stickyNav(){var e=document.getElementById("sticky-nav"),t=document.getElementsByClassName("sticky-btn");if(45<document.body.scrollTop||45<document.documentElement.scrollTop){e.classList.add("essay-nav-scroll");for(var s=0;s<t.length;s++)t[s].classList.add("essay-btn-scroll")}else for(e.classList.remove("essay-nav-scroll"),s=0;s<t.length;s++)t[s].classList.remove("essay-btn-scroll")}document.getElementById&&(onload=function(){setInterval("document.getElementById('current-year').firstChild.data = new Date().getFullYear()")})</script> <script>"serviceWorker"in navigator&&"refoundable.com"===window.location.hostname&&navigator.serviceWorker.register("/service-worker.js").then(function(e){console.log("ServiceWorker registration successful with scope: ",e.scope)}).catch(function(e){console.log("ServiceWorker registration failed: ",e)})</script> <script>!function(t,e){"function"==typeof define&&define.amd?define(function(){return e(t)}):"object"==typeof exports?module.exports=e:t.echo=e(t)}(this,function(u){"use strict";function d(t,e){if(function(t){return null===t.offsetParent}(t))return!1;var n=t.getBoundingClientRect();return n.right>=e.l&&n.bottom>=e.t&&n.left<=e.r&&n.top<=e.b}function c(){!i&&t||(clearTimeout(t),t=setTimeout(function(){s.render(),t=null},a))}var l,t,a,i,f,s={},h=function(){};return s.init=function(t){function e(t,e){return parseInt(t||e,10)}var n=(t=t||{}).offset||0,o=t.offsetVertical||n,r=t.offsetHorizontal||n;l={t:e(t.offsetTop,o),b:e(t.offsetBottom,o),l:e(t.offsetLeft,r),r:e(t.offsetRight,r)},a=e(t.throttle,250),i=!1!==t.debounce,f=!!t.unload,h=t.callback||h,s.render(),document.addEventListener?(u.addEventListener("scroll",c,!1),u.addEventListener("load",c,!1)):(u.attachEvent("onscroll",c),u.attachEvent("onload",c))},s.render=function(t){for(var e,n,o=(t||document).querySelectorAll("[data-echo], [data-echo-background]"),r=o.length,c={l:0-l.l,t:0-l.t,b:(u.innerHeight||document.documentElement.clientHeight)+l.b,r:(u.innerWidth||document.documentElement.clientWidth)+l.r},a=0;a<r;a++)n=o[a],d(n,c)?(f&&n.setAttribute("data-echo-placeholder",n.src),null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+n.getAttribute("data-echo-background")+")":n.src!==(e=n.getAttribute("data-echo"))&&(n.src=e),f||(n.removeAttribute("data-echo"),n.removeAttribute("data-echo-background")),h(n,"load")):f&&(e=n.getAttribute("data-echo-placeholder"))&&(null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+e+")":n.src=e,n.removeAttribute("data-echo-placeholder"),h(n,"unload"));r||s.detach()},s.detach=function(){document.removeEventListener?u.removeEventListener("scroll",c):u.detachEvent("onscroll",c),clearTimeout(t)},s})</script> <script>echo.init({offset:2500,throttle:250,unload:!1,callback:function(t,o){}})</script></body></html>